Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. NOBELPHARMA CO LTD
CRL
•NOBELPHARMA CO LTD

NOBELPHARMA CO LTD – FDA CRL

Record Details

The U.S. FDA issued a Complete Response Letter (CRL) to Nobelpharma Co., Ltd. regarding their New Drug Application (NDA 213478) for sirolimus topical gel, 0.2%, submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. The application cannot be approved in its current form due to several outstanding issues. Key deficiencies include product quality concerns, specifically regarding active pharmaceutical ingredient (API) assay results and the need to revise manufacturing process parameters with robust supporting data and scalability discussions. A critical unresolved issue is the mandatory facility inspection of TOYO PHARMACEUTICAL CO. LTD. in Osaka, Japan (FEI 3016419927) to assess compliance with Current Good Manufacturing Practices (CGMP). This inspection was delayed due to travel restrictions and must be completed before the application can be approved, irrespective of other deficiencies being addressed. Additionally, Nobelpharma is required to provide a comprehensive safety update encompassing all nonclinical and clinical studies, detailing significant changes in the safety profile, presenting combined new and original safety data, and including narratives for serious adverse events. Updates on exposure, worldwide safety experience, and translated foreign labeling are also necessary. Comments on proposed prescribing information are reserved until other issues are resolved, emphasizing conformity with labeling regulations. While the proposed proprietary name, Hyftor, was found acceptable, it must be resubmitted with the complete response. Nobelpharma must address all deficiencies and resubmit the application within one year. Approval is contingent upon satisfactory resolution of all issues, particularly the successful completion of the facility inspection.

Company
NOBELPHARMA CO LTD
Product type
Drugs
Office
Division of Dermatology and Dentistry
Person
  • Dana Dunn
View Company Profile

ID · 84c2bf51-97ab-4c32-a3b1-d5647ecad33e

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore NOBELPHARMA CO LTD
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.